ArticleProceedings of the National Academy of Sciences of the United States of America2022
Noninvasive detection of any-stage cancer using free glycosaminoglycans.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- The diagnostic utility of glycosaminoglycans (GAGs) in the early detection of cancer: a systematic review.PeerJ · 2024Pooled it
- Is There a Role for Machine Learning in Liquid Biopsy for Brain Tumors? A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Multi-cancer Detection Using Pattern Formation in Drying Body Fluids: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies.Technology in cancer research & treatmentPooled it
- Glycoinformatic Profiling of Label-Free Intact Heparan Sulfate Oligosaccharides.Molecular & cellular proteomics : MCP · 2026Article
- Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.Innovation (Cambridge (Mass.)) · 2026Article
- Liquid biopsy in lung cancer screening: rationale, progress, opportunities and challenges.Clinical and experimental medicine · 2025Review
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- Unlocking the potential of tumor-derived DNA in urine for cancer detection: methodological challenges and opportunities.Molecular oncology · 2025Review
- External Validation of Plasma Glycosaminoglycans as Biomarkers to Improve Lung Cancer Risk Stratification.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- New horizons at the interface of artificial intelligence and translational cancer research.Cancer cell · 2025Review
- High-throughput glycosaminoglycan extraction and UHPLC-MS/MS quantification in human biofluids.Nature protocols · 2025Review
- Multicancer Detection (MCD) Testing in Gastrointestinal Cancers: An Evolving Tool for Early Diagnosis.Current gastroenterology reports · 2025Review
- Genome-scale models in human metabologenomics.Nature reviews. Genetics · 2025Review
- Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.International journal of clinical oncology · 2025Review
- Modeling for understanding and engineering metabolism.QRB discovery · 2025Article
- Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine.Chemical reviews · 2024Review
- Urinary Free Glycosaminoglycans Identify Adults at High Risk of Developing Early-stage High-grade Bladder Cancer.European urology open science · 2024Article
- Discriminating Benign from Malignant Lung Diseases Using Plasma Glycosaminoglycans and Cell-Free DNA.International journal of molecular sciences · 2024Article
- Epigenetic Targeting of Heparan Sulfate 3-ACS pharmacology & translational science · 2024Article
- Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 15 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer mortality is exacerbated by late-stage diagnosis. Liquid biopsies based on genomic biomarkers can noninvasively diagnose cancers. However, validation studies have reported ~10% sensitivity to detect stage I cancer in a screening population and specific types, such as brain or genitourinary tumors, remain undetectable. We investigated urine and plasma free glycosaminoglycan profiles (GAGomes) as tumor metabolism biomarkers for multi-cancer early detection (MCED) of 14 cancer types using 2,064 samples from 1,260 cancer or healthy subjects. We observed widespread cancer-specific changes in biofluidic GAGomes recapitulated in an in vivo cancer progression model. We developed three machine learning models based on urine (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.